If your prostate cancer has reached nearby pelvic lymph nodes, you may still have several treatment options, but surgery may not always be the most appropriate first treatment.
Your treatment depends on your lymph-node involvement, PSA, cancer stage and whether the cancer has spread elsewhere. Your specialist may discuss surgery, radiotherapy, hormone therapy or a combination.
What Does It Mean When Prostate Cancer Has Spread to the Lymph Nodes?
If your prostate cancer has spread to nearby pelvic lymph nodes, it means some cancer cells have moved beyond your prostate. This is called N1 disease.
Regional pelvic lymph-node involvement is associated with a higher risk of recurrence and progression, but it is different from cancer that has spread to distant lymph nodes, bones or other organs. The number and location of affected nodes also help your specialist decide which treatment is right for you.
What Is the Difference Between N1 and Metastatic Prostate Cancer?
If your cancer has reached nearby pelvic lymph nodes, you have N1 disease. This does not automatically mean your cancer has spread throughout your body.
M1 disease means your cancer has spread to distant areas, such as distant lymph nodes, bones or other organs. If you have cN1M0 disease, your specialist may still recommend multimodal treatment with long-term cancer control as the aim, using local treatment together with systemic therapy.
What Is cN1 Prostate Cancer?
If conventional imaging suggests cancer in nearby pelvic lymph nodes before treatment, your cancer may be described as cN1. PSMA PET/CT can detect smaller nodal deposits and may identify molecular-imaging nodal disease, sometimes described as miN1.
If there is no distant spread, the cancer is M0. Your specialist will consider how the lymph-node involvement was detected alongside your PSA, Grade Group and other staging results when planning treatment.
What Does pN1 Mean After Prostate Surgery?
If cancer is found in your pelvic lymph nodes after they are removed and examined, your cancer is called pN1. The “p” means lymph-node involvement has been confirmed by pathological examination of tissue removed during surgery.
Your scans may not have shown the cancer beforehand because tiny deposits can be difficult to detect. Your next treatment will depend on how many lymph nodes are affected, your pathology results and your PSA after surgery.
What Do cN1, pN1 and M1a Mean?
Your nodal stage helps your team understand whether cancer is limited to regional pelvic lymph nodes or has reached more distant parts of your body.
| Term | What It Means | Why It Matters |
| cN1 | Regional pelvic lymph-node involvement is suspected or identified during clinical staging before treatment | Usually changes the initial treatment strategy and makes combined local and systemic treatment important |
| miN1 | Pelvic nodal disease is detected on molecular imaging such as PSMA PET/CT, sometimes when conventional imaging was negative | More sensitive imaging can identify lower-volume nodal disease, but treatment decisions can be less straightforward because much of the evidence underlying current cN1 recommendations comes from conventional imaging. |
| pN1 | Cancer is confirmed microscopically in regional lymph nodes removed during surgery | Postoperative treatment depends on nodal burden, pathology and PSA |
| M1a | Cancer is present in non-regional lymph nodes | This is classified as distant metastatic disease rather than regional N1 disease |
| M1b/M1c | Cancer has spread to bone or other distant sites | Systemic treatment becomes central to management |
Your specialist will interpret the nodal stage together with your PSA, Grade Group, tumour stage, scan findings and overall health.
Can You Still Have Robotic Surgery If Nodes Look Positive Before Treatment?
If conventional staging shows cancer in your pelvic lymph nodes before treatment, radiotherapy to the prostate and pelvis with long-term hormone therapy is usually the guideline-supported approach. For suitable cN1M0 patients, two years of abiraterone may also be recommended.
Surgery may still be discussed in selected cases. Your specialist will consider how the nodal disease was detected, your PSA, Grade Group, overall stage and general health before deciding what is appropriate for you.
What If Positive Lymph Nodes Are Discovered During the Operation?
If your lymph nodes look suspicious during surgery, your surgeon may still continue with the prostatectomy rather than automatically stopping. This can happen when your scans suggested that your nodes were clear before surgery.
If final pathology confirms cancer in the removed lymph nodes, this increases your recurrence risk, but it does not mean that the operation has failed. Current European guidance also advises against using intra-operative frozen-section analysis of lymph nodes simply to decide whether prostatectomy should be abandoned.
Why Are Pelvic Lymph Nodes Removed During Prostate Surgery?
If lymph-node dissection is indicated, your surgeon may remove regional pelvic lymph nodes to provide more accurate pathological staging after prostatectomy. Small cancer deposits may not show on scans, so testing the removed nodes can give you a clearer answer.
If cancer is found, your pathology report will show how many nodes were affected. This helps your specialist decide whether you need any further treatment.
Can Removing Positive Lymph Nodes Cure the Cancer?
Pelvic lymph-node dissection removes the nodes within the surgical field and provides valuable staging information. However, removing positive nodes alone cannot guarantee that all prostate cancer cells have been removed from your body.
Your PSA, Grade Group, tumour stage and number of positive nodes will help your specialist decide whether you need additional treatment or close monitoring.
Why Does the Number of Positive Lymph Nodes Matter?
The number of lymph nodes containing cancer helps your specialist understand your risk more clearly. Your results can also influence whether you need monitoring or additional treatment after surgery.
- Nodal Burden: Cancer in one or two lymph nodes may carry a different risk from cancer found in several nodes.
- Pathology Results: Your report shows how many lymph nodes were removed and how many contained prostate cancer.
- PSA Monitoring: Your PSA after surgery helps your specialist assess whether further treatment may be needed.
- Treatment Planning: Your Grade Group, tumour stage, surgical margins and number of positive nodes all help guide your next steps.
Your specialist will consider your lymph-node findings alongside your other cancer results rather than using them alone. This helps create a follow-up and treatment plan suited to your individual situation.
How Can PSMA PET/CT Change the Picture?
A PSMA PET/CT scan can help your doctor find prostate cancer in lymph nodes that may not show clearly on standard scans. This can give you a more detailed picture of where your cancer has spread.
Finding very small nodes only on PSMA PET/CT can make treatment decisions more complex because much of the evidence for cN1 treatment is based on conventional imaging. Your specialist will therefore interpret PSMA findings alongside your PSA, Grade Group, tumour stage and other results before recommending the most suitable treatment approach.
Evidence Note
The prospective proPSMA trial randomised 302 men with high-risk prostate cancer before curative-intent treatment. PSMA PET/CT had an overall staging accuracy of 92% compared with 65% for conventional CT and bone scanning. It also changed planned treatment more often, in 28% of patients compared with 15% after conventional imaging.
This shows why PSMA PET/CT can materially change treatment planning in high-risk prostate cancer. However, a negative scan cannot completely exclude microscopic lymph-node involvement.
What Other Cancer Features Affect Whether Surgery Has a Role?
Your lymph nodes are only one part of the picture. Your PSA, Grade Group, tumour stage and scan results all help your specialist understand how aggressive your cancer may be.
Your general health and ability to recover from major surgery also matter. Your team will consider all these factors to decide whether robotic surgery could meaningfully contribute to your overall treatment.
Is Radiotherapy Usually Preferred When Nodes Are Positive Before Treatment?
If your pelvic lymph nodes are known to contain cancer before treatment, your specialist may recommend radiotherapy to the prostate and pelvis with hormone therapy. This treats both the main cancer and the regional lymph-node area.
Surgery may still be discussed in selected cases. Your cancer stage, PSA, Grade Group, scans and general health will help determine which approach is most suitable for you.
Why Might Hormone Therapy Be Needed?
If your prostate cancer has reached your lymph nodes, hormone therapy (ADT) may be recommended to control cancer cells that could be elsewhere in your body.
Whether you need ADT depends on when the nodal disease was found, your PSA, Grade Group, pathology and wider treatment plan.
UK Guidance Note
For cN1M0 prostate cancer, current European guidance recommends radiotherapy to the prostate and pelvic lymph nodes together with long-term androgen deprivation therapy and two years of abiraterone.
In the UK, NICE NG131 has not yet incorporated this newer recommendation for high-risk hormone-sensitive non-metastatic disease. NICE reviewed this area in 2025 and confirmed that NG131 will be updated to consider newer evidence on abiraterone and docetaxel for high-risk hormone-sensitive non-metastatic prostate cancer. The exact treatment offered can therefore depend on individual clinical circumstances and local commissioning.
Could You Need Radiotherapy After Robotic Surgery?
Yes, you may need radiotherapy if your removed lymph nodes contain cancer. It can target the prostate bed and, in some cases, the pelvic lymph-node area.
Your PSA, number of positive nodes, Grade Group, tumour stage and surgical margins will help your specialist decide whether radiotherapy and hormone therapy could benefit you.
Can Some Men With Positive Nodes Be Monitored After Surgery?
Yes. If you have had an extended lymph-node dissection, no more than two positive lymph nodes are found and your PSA is undetectable after surgery, your specialist may consider close monitoring instead of immediate additional treatment.
You would still need regular PSA checks. If your PSA starts to rise, your team can discuss further treatment such as radiotherapy or hormone therapy.
Research Insight
A systematic review by Marra and colleagues assessed 26 studies involving 12,537 men with pN1 prostate cancer after radical prostatectomy and pelvic lymph-node dissection. The evidence suggested that postoperative management should be adapted to individual risk: selected men with a low burden of nodal disease could initially be observed, while radiotherapy with or without androgen deprivation therapy appeared more beneficial in men with more advanced local disease or a greater number of positive nodes.
Most of the included studies were retrospective, so the review does not establish one treatment as best for every patient. It supports considering the number of positive nodes, Grade Group, pathological stage, surgical margins and postoperative PSA together when planning further treatment.
Why Is Your PSA So Important After Surgery?
After your prostate is removed, your PSA should fall to a very low or undetectable level. If PSA remains detectable after surgery, your specialist will assess the level and trend because this may indicate persistent prostate cancer.
An undetectable PSA is reassuring, but you will still need regular monitoring. Your PSA result, number of positive lymph nodes and pathology findings help your specialist decide whether you need further treatment.
What Happens If Your PSA Remains Detectable?
If your PSA remains detectable after surgery, your specialist may repeat the test to see whether it is falling, stable or rising. A PSMA PET/CT may also be considered to look for remaining cancer.
Depending on the findings, you may need radiotherapy, hormone therapy or both. A detectable PSA does not mean further treatment cannot still be effective.
Is Robotic Surgery Better Than Radiotherapy for Node-Positive Cancer?
If your pelvic lymph nodes are known to contain cancer before treatment, radiotherapy with systemic treatment is often recommended rather than surgery. Research has not shown that robotic surgery is clearly better in this situation.
If positive nodes are discovered during or after surgery, your options are different. Your specialist will use your pathology and PSA to decide whether monitoring, radiotherapy, hormone therapy or a combination may benefit you.
What Should You Ask Before Considering Robotic Prostate Surgery?
Ask how your lymph-node involvement was detected and what your PSA, Grade Group and overall stage mean for you.
You should also ask whether surgery could be your only treatment or whether radiotherapy, hormone therapy or both may be needed afterwards.
Myth vs Fact
| Myth | Fact |
| Any prostate cancer in a lymph node means you have widespread metastatic disease. | Cancer in regional pelvic lymph nodes is classified as N1. Cancer in non-regional lymph nodes is classified as M1a metastatic disease. |
| If a pelvic lymph node is positive, prostate surgery is always impossible. | Known cN1 disease is usually treated with a radiotherapy-based multimodal approach, but surgery may still have a role in selected circumstances or when pN1 disease is discovered unexpectedly after prostatectomy. |
| Removing positive lymph nodes guarantees that the cancer has been cured. | Pelvic lymph-node dissection provides important pathological staging, but removing involved nodes does not guarantee that microscopic cancer is absent elsewhere. |
| A negative PSMA PET/CT proves your lymph nodes are clear. | PSMA PET/CT is more accurate than conventional imaging, but very small microscopic lymph-node metastases can still be missed. |
| Every man with pN1 disease needs immediate radiotherapy and hormone therapy. | Postoperative management is individualised. Selected patients with no more than two positive nodes and an undetectable PSA may be considered for observation after an extended lymph-node dissection. |
| An undetectable PSA means follow-up is no longer necessary. | An undetectable PSA is reassuring, but regular PSA monitoring remains important because lymph-node-positive disease carries a higher recurrence risk. |
Key Takeaways
- N1 means prostate cancer has reached regional pelvic lymph nodes; non-regional lymph nodes are M1a metastatic disease.
- For conventional-imaging cN1M0 disease, radiotherapy with long-term systemic treatment is generally guideline-supported.
- PSMA PET/CT improves staging but cannot exclude every microscopic lymph-node metastasis.
- Pelvic lymph-node dissection provides valuable staging but does not guarantee cure of node-positive disease.
- After pN1 disease is found, options may include ADT, radiotherapy plus ADT or observation in selected low-burden cases.
- Your positive-node count, Grade Group, stage, margins and postoperative PSA help guide further treatment.
Frequently Asked Questions
1. Can You Have Robotic Prostate Surgery If Cancer Has Spread to the Lymph Nodes?
You may still have treatment options if your prostate cancer has reached nearby pelvic lymph nodes, but robotic surgery is not always the preferred approach. Your specialist will consider your cancer stage, PSA, scans and overall health.
2. What Does N1 Prostate Cancer Mean?
N1 prostate cancer means your cancer has spread to nearby pelvic lymph nodes. It is different from M1 disease, where cancer has spread to distant parts of your body.
3. Can You Have Robotic Surgery If Your Lymph Nodes Look Positive on a Scan?
If your scans show positive pelvic lymph nodes before treatment, robotic surgery is not usually the standard first treatment. Your specialist may discuss radiotherapy with hormone therapy or other treatments depending on your individual cancer.
4. What Does pN1 Mean After Robotic Prostate Surgery?
pN1 means your pathologist has found prostate cancer in one or more lymph nodes removed during surgery. The number of affected nodes and other pathology findings help your specialist assess your risk.
5. Can Removing Positive Lymph Nodes Cure Your Prostate Cancer?
Removing involved lymph nodes provides important staging information, but it does not guarantee that microscopic cancer is absent elsewhere. You may therefore need further treatment or monitoring.
6. Why Does the Number of Positive Lymph Nodes Matter?
The number of lymph nodes containing cancer can help your specialist understand your risk of recurrence. Your doctor will consider this alongside your PSA, Grade Group, tumour stage and other pathology findings.
7. Could You Need Radiotherapy After Robotic Prostate Surgery?
Yes, you may need radiotherapy if your lymph nodes contain cancer or other features suggest a higher risk of recurrence. Your specialist may also consider hormone therapy depending on your individual results.
8. Why Is PSA Important After Surgery?
Your PSA should fall to a very low or undetectable level after your prostate is removed. If it remains detectable or starts rising, your specialist may investigate further and discuss additional treatment.
9. Can You Be Monitored If You Have Positive Lymph Nodes?
In selected cases, your specialist may recommend close PSA monitoring, particularly after an extended lymph-node dissection when no more than two nodes are positive and your postoperative PSA is undetectable. Your follow-up will depend on your overall pathology and risk.
10. Is Robotic Surgery Better Than Radiotherapy for Node-Positive Cancer?
There is no single treatment approach that is suitable for everyone with node-positive prostate cancer. Your specialist will compare surgery, radiotherapy, hormone therapy and possible combinations based on your cancer and overall health.
Final Thoughts: Understanding Robotic Prostate Surgery for Lymph Node-Positive Cancer
If your prostate cancer has reached nearby pelvic lymph nodes, you still have treatment options, although robotic surgery may not be the usual first choice. Your specialist will consider your nodal disease, PSA, Grade Group, scans and health when planning treatment.
If you are considering robotic prostate surgery in London, Prostate Clinic London can discuss your diagnosis and explain which treatment options may be suitable for you.
References:
- National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Published 9 May 2019; last updated 15 December 2021. Available at: https://www.nice.org.uk/guidance/ng131
- Marra, G., Valerio, M., Heidegger, I., Tsaur, I., Mathieu, R., Ceci, F., Ploussard, G., van den Bergh, R.C.N., Kretschmer, A., Thibault, C. et al. (2020) ‘Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review’, European Urology Oncology, 3(5), pp. 565–581. Available at: https://pubmed.ncbi.nlm.nih.gov/32933887
- The Royal College of Pathologists (2024) G084 Dataset for histopathology reports for prostatic carcinoma. Version 4, October 2024. Available at: https://www.rcpath.org/resourceLibrary/g084-dataset-for-histopathology-reports-for-prostatic-carcinoma.html
- European Association of Urology (EAU) (2026) EAU Guidelines on Prostate Cancer: Treatment. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
- Attard, G., Murphy, L., Clarke, N.W., Cross, W., Jones, R.J., Parker, C.C., Gillessen, S., Cook, A., Brawley, C., Amos, C.L. et al. (2022) ‘Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol’, The Lancet, 399(10323), pp. 447–460. Available at: https://pubmed.ncbi.nlm.nih.gov/34953525
- Hofman, M.S., Lawrentschuk, N., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J.M., Frydenberg, M., Shakher, R. et al. (2020) ‘Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study’, The Lancet, 395(10231), pp. 1208–1216. Available at: https://pubmed.ncbi.nlm.nih.gov/32209449
- National Institute for Health and Care Excellence (NICE) (2025) May 2025 and August 2025 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131). Available at: https://www.nice.org.uk/guidance/ng131/evidence/may-2025-exceptional-surveillance-of-prostate-cancer-diagnosis-and-management-nice-guideline-ng131-15368818141